BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
|
|
BOM : 524663     NSE :      | |
LT :  
    Long Term Analysis
Fundamentals : Bad
Valuation : Bad [Stock is Expensive] Debt : High |
Updated: |
ST :  
    Short Term Analysis
Quarterly Earnings Trend : Downward
Price Momentum : Downward Pledged Shares : None or < 25% |
Aug 30,2024 |
Price(EOD): ₹ 29.49
This is the End-of-Day (EOD) Stock Price updated daily by 7 pm IST.
|
Pharmaceuticals & Drugs |
MCap: ₹ 127.40 Cr |
Industry Peers & Returns | 1W | 1M | 1Y |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION | -1.7% | -7.1% | 28% |
SUN PHARMACEUTICAL INDUSTRIES | 2.7% | 6% | 62.4% |
CIPLA | 3.9% | 7.3% | 33.9% |
DR REDDYS LABORATORIES | 1.2% | 4.2% | 20.1% |
ZYDUS LIFESCIENCES | 1.8% | -9.5% | 80.1% |
DIVIS LABORATORIES | 3.2% | 3.5% | 37.8% |
FUNDAMENTAL ANALYSIS OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
 Y : Last Audited Annual/Yearly Data
TTM i.e. Trailing Twelve Months is calculated using last 4 quarterly data and is a good substitute to track last 4 Qtr Annual result before the subsequent year data is published and audited.
Learn More
VALUATION OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
 Ratio | Standalone | |
---|---|---|
P/E P/B P/S |
-7.37
P/E Calculated based on Trailing Twelve Months (TTM) Earnings of Rs -17.27 Cr
[Latest Qtr - Sep2023 - Standalone Results ] 1.44
P/B Calculated based on Book Value of Rs 88.21 Cr
[Latest Year - Mar2023 - Standalone Results ] 4.81
P/S Calculated based on Trailing Twelve Months (TTM) Revenues of Rs 0.00 Cr
[Latest Qtr - Sep2023 - Standalone Results ] |
|
Financial Ratios → |
Model | Discount(-)/ Premium(+) |
---|---|
EV/EBIDTA EV/Sales Price/Sales |
NA NA (-ve EV) 1436% |
SHARE PRICE MOMENTUM OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION vs SENSEX
DEBT OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Year | Debt/Equity ratio | |
---|---|---|
Standalone | Consolidated | |
2023 2022 2021 Avg_3yrs |
-3.05 -12.18 11.56 -1.22 |
- - - - |
[Last Annual Data : Mar2023]
|
||
Financial Ratios → |
PLEDGED PROMOTER SHARES OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Pledged Promoter Shares |
0 % | |
---|---|---|
As on : Dec2023 | ||
If less than 25% | Good |
|
If between 25% and 50% | Neutral | |
If greater than 50% | Bad | |
Shareholding Pattern → |
QTRLY RESULTS OF BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Standalone | Q-o-Q | Y-o-Y |
---|---|---|
Revenue Op Profit Profit Before Tax Profit After Tax |
NA -8.69% -11.38% -7.22% |
-100% 2.94% -5.43% 1.58% |
QtrlyTrend |
-3 | |
Latest Qtr: Sep2023 | ||
Quarterly Result Analysis → |
BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION related INDICES
You may also like the below Video Courses
FAQ about BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION
Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION good for long term investment?
As on Aug 30,2024, the Fundamentals of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION look Poor and hence it may not be good for long term investment ! See Financial Performance of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION . Please look at the other parameters such as Valuation, Price Momentum, News & Corporate Governance and/or consult an Investment Advisor before taking an investment decision!Is BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION UnderValued or OverValued?
As on Aug 30,2024, BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION is Over Valued based on the estimates of intrinsic value and hence may not be a good buying opportunity according to Share Valuation at this time!What is the Intrinsic Value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION ?
As on Aug 30,2024, the Intrinsic Value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION is Rs. 1.92 estimated based on Median of the 3 historical models.Fair Value [Median EV / EBIDTA Model] : Rs. -9.36
Fair Value [Median EV / Sales Model] : Rs. -3.96
Fair Value [Median Price / Sales Model] : Rs. 1.92
Estimated Median Fair Value of BHARAT IMMUNOLOGICALS & BIOLOGICALS CORPORATION : Rs. 1.92
The fair value of any stock is always subjective and should, in no way, be taken as a recommendation to buy/sell the same.